Exchange: NASDAQ·Updated 07:51 PM EDT
RVMD logo

RVMDRevolution Medicines Inc

$189.24
$1.73
(0.92%)
Today
Closed $189.24
$0.20
(0.11%)
After Hours
EarningsAug 5
Mkt Cap$40.23B
Vol3.19M
News
all
press releases
Tango Therapeutics Rides a New Precision Oncology Trend in 2026
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Zacks
News Placeholder
More News
News Placeholder
Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
Zacks
News Placeholder
TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
Zacks
News Placeholder
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Key PointsRevolution Medicines' cancer drugs in development could establish new standards of care in some niches...
Nasdaq News: Markets
News Placeholder
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
Zacks
News Placeholder
Can Revolution Medicines Be a Game-Changer Stock?
Key PointsRevolution Medicines' promising pancreatic cancer therapy could be approved later this year...
Nasdaq News: Markets
News Placeholder
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Zacks
News Placeholder
TNGX Stock Hits All-Time High – Wolfe Research Calls Tango Therapeutic’s Pancreatic Cancer Trial Data ‘Groundbreaking’
Tango Therapeutics’ experimental cancer drug Vopimetostat, in combination with Daraxonrasib, achieved a 92% objective response rate in patients with advanced pancreatic cancer.
Stocktwits
News Placeholder
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?
Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller...
Yahoo! Finance: News
News Placeholder
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
<
1
2
...
>

Advertisement|Remove ads.